Praxis Precision Medicines (PRAX) EBIT Margin (2023 - 2024)
Praxis Precision Medicines' quarterly EBIT Margin came in at 856.97% in Q4 2024, up 454225.0% year-on-year from N/an in Q1 2024, and up 95.45% quarter-over-quarter from 18819.54% in Q3 2024.
Praxis Precision Medicines has reported EBIT Margin for 2 years, with the latest figure at 856.97% in Q4 2024.
- For the quarter ending Q4 2024, EBIT Margin rose 454225.0% year-over-year to 856.97%; the trailing twelve-month figure through Sep 2025 stood at 3927.51% (up 629149.0% YoY), and the FY2024 full-year result was 2340.29%, up 282412.0% from the prior year.
- EBIT Margin for Q4 2024 stood at 856.97%, up from 18819.54% in the prior quarter.
- The five-year high for EBIT Margin was 856.97% in Q4 2024, with the low at 18819.54% in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Praxis Precision Medicines | 10.11 Bn | 9.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -856.97% |
| Sep 30, 2024 | -18,819.54% |
| Jun 30, 2024 | -10,500.84% |
| Mar 31, 2024 | -9,718.33% |
| Dec 31, 2023 | -5,399.22% |
| Sep 30, 2023 | -5,452.14% |
| Jun 30, 2023 | -4,476.31% |
| Mar 31, 2023 | -5,577.01% |